ArticleAmerican journal of cancer research2026
Real-world outcomes of consolidative radiotherapy following first-line chemo-immunotherapy in metastatic non-small cell lung cancer: a retrospective cohort study.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role and efficacy of consolidative radiotherapy (CRT) in patients with metastatic non-small cell lung cancer (mNSCLC) treated with first-line chemo-immunotherapy remain to be clarified. In this retrospective cohort study, we divided mNSCLC patients who achieved disease control with initial chemo-immunotherapy into CRT and non-CRT groups. Propensity score matching was employed to balance baseline characteristics. Results showed that the median overall survival (OS) was significantly longer in the CRT group (38.5 months) compared to the non-CRT group (25.1 months) (HR=0.48, P=0.004). Similarly, median progression-free survival (PFS) was 16.2 months in the CRT group versus 9.8 months in the non-CRT group (HR=0.52, P=0.005). CRT was identified as an independent favorable prognostic factor, with OS benefits consistent across all subgroups. Safety analysis revealed no significant difference in the incidence of grade ≥3 adverse events between the groups. These findings indicate that consolidative radiotherapy following first-line chemo-immunotherapy is associated with significantly improved survival outcomes in mNSCLC patients, demonstrating a favorable risk-benefit profile in real-world practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.